Abstract
BackgroundThe body surface area (BSA) is taken as a measure for the effective contact area for dosing in hyperthermic intraperitoneal chemotherapy (HIPEC). Currently, the pharmacokinetic effect of the reduced peritoneal surface area (PSA) after cytoreductive surgery (CRS) during HIPEC remains unclear. Here a proprietary software solution (PEritoneal SUrface CAlculator (PESUCA)) to quantify the resected PSA in patients with peritoneal surface malignancies (PSM) undergoing CRS and HIPEC is presented.MethodsThe PESUCA tool was programmed as a desktop and online software solution. The applicability was evaluated in 36 patients. The programming-algorithm is briefly summarized as follows: (1) calculation of BSA, (2) correlation to PSA, (3) calculation of the relative proportion of 40 different anatomical regions to total PSA before CRS, (4) instantaneous input of each resected proportion in the 40 anatomical regions during CRS, and (5) determination of the resected and remaining PSA after CRS.ResultsThe proof of concept revealed a mean PSA of all patients before CRS of 18,741 ± 321 cm2 compared to 13,611 ± 485 cm2 after CRS (p<0.0001). Patients’ supramesocolic and inframesocolic visceral and parietal peritoneal area before and after CRS procedure were quantitatively determined.ConclusionsHere the first tool that enables detailed PSA quantification in patients with PSM undergoing CRS is presented. This makes the software a valuable contribution to ensue more accurate assessment and improved comparability of peritoneal disease extent. Furthermore, after external validation, PESUCA could be the basis for dose adjustment of intraperitoneal chemotherapy regimens based on the remaining PSA after CRS.
Highlights
During the last two decades, new treatment protocols that combine cytoreductive surgery (CRS) and perioperative hyperthermic intraperitoneal chemotherapy (HIPEC) for patients suffering from peritoneal surface malignancies (PSM) were developed
After external validation, PEritoneal SUrface CAlculator (PESUCA) could be the basis for dose adjustment of intraperitoneal chemotherapy regimens based on the remaining peritoneal surface area (PSA) after CRS
To the best of our knowledge, here we present the first software solution (PESUCA) to quantify the individual PSA before and after CRS in patients with PSM
Summary
During the last two decades, new treatment protocols that combine cytoreductive surgery (CRS) and perioperative hyperthermic intraperitoneal chemotherapy (HIPEC) for patients suffering from peritoneal surface malignancies (PSM) were developed. Since HIPEC procedures were first developed in the 1980s, multiple studies have been conducted resulting in widespread discussions about its real benefit and associated patients’ risks. Eight parameters affecting HIPEC efficacy are described so far: choice of chemotherapeutic agent, carrier solution, dosing regimen, perfusate volume, temperature, procedure duration, delivery technique, and adequate patient selection [5, 6]. The pharmacokinetic effect of the reduced peritoneal surface area (PSA) after cytoreductive surgery (CRS) during HIPEC remains unclear. A proprietary software solution (PEritoneal SUrface CAlculator (PESUCA)) to quantify the resected PSA in patients with peritoneal surface malignancies (PSM) undergoing CRS and HIPEC is presented. The programming-algorithm is briefly summarized as follows: (1) calculation of BSA, (2) correlation to PSA, (3) calculation of the relative proportion of 40 different anatomical regions to total PSA before CRS, (4) instantaneous input of each resected proportion in the 40 anatomical regions during CRS, and (5) determination of the resected and remaining PSA after CRS
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
